GlaxoSmithKline has agreed to pay $105m to more than 40 US states to settle allegations of unlawful marketing, ending a long saga in which the UK company was accused of providing lavish incentives for salesmen and doctors to promote its drugs for unauthorised purposes.
英国制药集团葛兰素史克(GlaxoSmithKline，简称：GSK)已同意向美国40多个州支付1.05亿美元，以了结对其非法营销的指控，从而结束了一场旷日持久的诉讼战，GSK被控向销售人员和医生提供慷慨的激励举措，以推销其药物用于未经批准的用途。
您已阅读13%（393字），剩余87%（2522字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。